A Study of TL118 for Solid Tumors with NTRK Gene Fusions
This study is looking at how well a drug called TL118 works and if it's safe for people with certain solid tumors. TL118 is a capsule taken by mouth. It targets specific changes in your genes (NTRK gene fusions) that can cause cancer to grow. To join, you must be 18 or older and have a solid tumor with an NTRK gene fusion. The main goal is to see how many people respond to TL118, with responses measured for up to 24 months. The study is currently unclear about its recruitment status and plans to enroll about 60 participants.
- Study design
- This study is an interventional study, meaning participants will receive a specific treatment. It aims to enroll 60 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your response to treatment will be measured from before you start the drug up to about 24 months after your last dose.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
At a glance
Conditions
NCT06010342
Where you'd take part
This study runs at 19 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Adventist Health Glendale
Glendale, Californiano site contact published
Recruiting
Affiliated Cancer Hospital and Institute of Guangzhou Medical University
Guangzhou, Guangdong, Chinano site contact published
Recruiting
Affiliated Cancer Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, Chinano site contact published
Recruiting
Beijing Cancer Hospital
Beijing, Beijing Municipality, Chinano site contact published
Recruiting
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, Chinano site contact published
Recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, Chinano site contact published
Recruiting
Harbin medical university cancer hospital
Harbin, Heilongjiang, Chinano site contact published
Recruiting
Hunan Cancer Hospital
Changsha, Hunan, Chinano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Objective Response Rate (ORR)Pre-dose up to approximately 24 months post-dose